Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world check: does polatuzumab help chinese lymphoma patients?

NCT ID NCT05954910

Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study follows 1,000 Chinese adults with diffuse large B-cell lymphoma (a fast-growing blood cancer) who are receiving polatuzumab as part of their routine care. Researchers are tracking how long patients stay cancer-free after treatment and noting any side effects. The goal is to see how well the drug works outside of controlled clinical trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who will be treated with polatuzumab (known as being recommended and having the intention to be treated with polatuzumab at the time of signing informed consent) or have initiated polatuzumab treatment within three months prior to enrollment and after the indication approval will be observed in this study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be diagnosed as DLBCL * Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy according to investigator's judgment * Cohort 2: diagnosis as DLBCL but could not be classified into unfit/frail * Cohort 3: relapse or refractory to previous treatment Exclusion Criteria: * Participant who currently participates in or with plan to participate in any interventional clinical trial * Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Inner Mongolia Medical University

    RECRUITING

    Hohhot, 010000, China

  • Beijing Hospital of Ministry of Health

    ACTIVE_NOT_RECRUITING

    Beijing, 100730, China

  • Beijing Tongren Hospital, Capital Medical University

    ACTIVE_NOT_RECRUITING

    Beijing, 100730, China

  • China Medical University (CMU) First Affiliated Hospital

    RECRUITING

    Shenyang, 110001, China

  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University

    ACTIVE_NOT_RECRUITING

    Xi'an, 710061, China

  • Guizhou Cancer Hospital

    RECRUITING

    Guiyang, 550004, China

  • Hainan Cancer Hospital

    RECRUITING

    Haikou, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, China

  • Jiangsu Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Nanjing, 211100, China

  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)

    ACTIVE_NOT_RECRUITING

    Nanjing, 210029, China

  • Jiangxi Cancer Hospital

    RECRUITING

    Nanchang, 330029, China

  • Peking Union Medical College Hospital

    ACTIVE_NOT_RECRUITING

    Beijing, 100032, China

  • Peking University Third Hospital

    RECRUITING

    Beijing, 100191, China

  • Ruijin Hospital Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, 200025, China

  • Shanxi Province Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Taiyuan, 030013, China

  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital

    ACTIVE_NOT_RECRUITING

    Chengdu, 610072, China

  • The Affiliated Hospital Of Qingdao University

    RECRUITING

    Qingdao, DUMMY_VALUE, China

  • The Affiliated Hospital of Xuzhou Medical University

    RECRUITING

    Xuzhou, China

  • The First Bethune Hospital of Jilin University

    ACTIVE_NOT_RECRUITING

    Changchun, China

  • The Fourth Hospital of Hebei Medical University

    ACTIVE_NOT_RECRUITING

    Shijiazhuang, China

  • Third Xiangya Hospital of Central South University

    RECRUITING

    Changsha, China

  • Tianjin Cancer Hospital

    RECRUITING

    Tianjin, 300060, China

  • Tianjin Medical University General Hospital

    RECRUITING

    Tianjin, 300052, China

  • Tongji Hospital of Tongji University

    ACTIVE_NOT_RECRUITING

    Shanghai, 200065, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    ACTIVE_NOT_RECRUITING

    Wuhan, 430022, China

  • Wuxi People's Hospital

    RECRUITING

    Wuxi, 214023, China

  • Xiangya Hospital of Centre-South University

    ACTIVE_NOT_RECRUITING

    Changsha, 410008, China

  • Xinjiang Medical University Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Ürümqi, 830011, China

  • Zhujiang Hospital, Southern Medical University

    ACTIVE_NOT_RECRUITING

    Guangzhou, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.